MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
May 07, 2024 08:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3...
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 02, 2024 07:30 ET
|
Arbutus Biopharma Corporation
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001...
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
May 01, 2024 07:30 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...